Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225848 | 0.93 | MAP2K1 (0.67) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3226545 | 0.93 | IGF1R (0.69) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3224515 | 0.92 | MAP2K1 (0.68) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3229863 | 0.90 | MAP2K1 (0.61) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3219183 | 0.90 | MAP2K1 (0.71) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3229188 | 0.90 | MAP2K1 (0.64) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3225217 | 0.89 | MAP2K1 (0.61) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3232470 | 0.88 | IGF1R (0.59) | IGF1RMAP2K1IKBKBEGFRLYN | |
| SCHEMBL3230924 | 0.86 | MAP2K1 (0.64) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL3229379 | 0.85 | MAP2K1 (0.62) | IGF1RMAP2K1IKBKBEGFRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010030835-A2 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH | 2004-09-09 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | IGF1R 1028/4885MAP2K1 568/4885IKBKB 557/4885 |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | IGF1R 591/4885MAP2K1 401/4885IKBKB 477/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | IGF1R 1028/4885MAP2K1 568/4885IKBKB 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.